

Czech Republic

Population (January 2013):	10 516 125
Human development Index (2013):	0.861
HAV vaccine recommendations:	HAV vaccination is recommended for susceptible individuals with no history of vaccination. Vaccination is mandatory for specific at risk groups
Seroprevalence studies by quality score:	score 0: 1 studies score 1: 5 studies score 2: 2 studies
Seroprevalence studies timeframe:	1992–2004

Seroprevalence assessment: **very low**
Incidence assessment: **low**
Susceptibility in adults: **high**

No studies were identified estimating HAV seroprevalence before 1990 in the Czech Republic. Of the five studies investigating HAV seroprevalence in the period 1990 and 2000, two sampled military personnel only and three included the general population. All studies estimated the seroprevalence to be below 30% by 30 years of age (Czech Republic_FFfigure 1). After 2000, the two studies retrieved provided very similar seroprevalence estimates. According to these, the HAV seroprevalence by the age of 30 was below 20%, reaching values above 50% in the age group 50–59. No epidemiological transition is evident from the graph in the recent decades. The Czech Republic is a very low endemicity country and has been so since the 1990s.

Czech Republic_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Reported incidence suggests HAV was circulating in the country until the late 1980s (reported incidence above 20/100 000 until 1989) and has decreased since. According to TESSy and available studies (Hubalek 2005, Castkova 2009) reported incidence was well below 10/100 000 after 2000 (Czech Republic_FFfigure 2). A ten-fold increase in reported incidence was registered during 2008–2009, as compared to the previous five-year period.


The susceptibility was estimated to be above 70% by the age of 30 and around 50% at the age of 50. Therefore the overall susceptibility in adults is considered high.

Czech Republic_Figure 1 (panel a). Summary of seroprevalence in Czech Republic, by age and time period


Panel a.1: 1975–1989

No data available


Panel a.2: 1990–1999




Panel a.3: 2000–2013



Czech Republic _Figure 1 (panel b). Summary of seroprevalence in Czech Republic 1975-2013, by age and time period



Czech Republic _Figure 2. Reported incidence of hepatitis A, Czech Republic, 1975–2013*



*National data source: <http://uzis.cz/en/catalogue/infectious-diseases>

Bibliography

1. Beran J, Douda P, Gal P, Rychly R, Prymula R, Splino M. The seroprevalence of the "total" anti-HAV antibody in the Czech UNPRO Forces (1991-1995). *Acta Medica (Hradec Kralove)*. 1996;39(1):35-9.
2. Beran J, Douda P, Prymula R, Gal P, Rychly R, Splino M. Hepatitis A vaccination by Havrix in the Czech U.N. Troops according to data of seroprevalence in 1991-1995. *Cent Eur J Public Health*. 1996 May;4(2):87-90.
3. Beran J, Douda P, Prymula R, Splino M, Gal P, Rychly R. [Seroprevalence of anti-hepatitis A antibodies in Czech soldiers serving in U.N. forces--suggestions for a hepatitis A vaccination schedule]. *Epidemiol Mikrobiol Imunol*. 1995 Dec;44(4):165-8.
4. Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. *Eur J Epidemiol*. 1999 Oct;15(9):805-8.
5. Castkova J, Benes C. Increase in hepatitis A cases in the Czech Republic in 2008 - an update. *Euro Surveill*. 2009 Jan 22;14(3).
6. Chlibek R, Cecetkova B, Smetana J, Prymula R, Kohl I. [Seroprevalence of antibodies against hepatitis A virus and hepatitis B virus in nonvaccinated adult population over 40 years of age]. *Epidemiol Mikrobiol Imunol*. 2006 Aug;55(3):99-104.
7. Hubalek Z. North Atlantic weather oscillation and human infectious diseases in the Czech Republic, 1951-2003. *Eur J Epidemiol*. 2005;20(3):263-70.
8. Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, et al. Comparative hepatitis A seroepidemiology in 10 European countries. *Epidemiol Infect*. 2012 Dec;140(12):2172-81.
9. Nemecek V, Castkova J, Fritz P, Linhartova A, Svandova E, Sramova H, et al. The 2001 serological survey in the Czech Republic--viral hepatitis. *Cent Eur J Public Health*. 2003 Dec;11 Suppl(SUPPL.):S54-61.
10. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. *J Travel Med*. 2007;14(3):181-7.
11. Pazdiora P. [Imported viral hepatitis A and B in the Czech Republic 1994-1999]. *Epidemiol Mikrobiol Imunol*. 2001 Feb;50(1):17-21.
12. Pazdiora P, Fránová D. Viral Hepatitis A in the West Bohemian Region in 1982 - 1996. Serological Investigations in the General Population and in Workers Engaged in Child Care. *Cesko-Slovenska Pediatrie*. 1998;53(2):86-9.